Search

Your search keyword '"McGuire DK"' showing total 521 results

Search Constraints

Start Over You searched for: Author "McGuire DK" Remove constraint Author: "McGuire DK"
521 results on '"McGuire DK"'

Search Results

2. Ertugliflozin and slope of chronic egfr prespecified analyses from the randomized vertis cv trial

3. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

4. Risk factors for kidney disorders in patients with type 2 diabetes at high cardiovascular risk: An exploratory analysis (DEVOTE 12)

5. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

7. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes

8. Glomerular Filtration Rate and Associated Risks of Cardiovascular Events, Mortality, and Severe Hypoglycemia in Patients with Type 2 Diabetes: Secondary Analysis (DEVOTE 11)

9. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

11. Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10)

12. Corrections needed to 2016 ESC and AHA guidelines on heart failure

13. Assessing the safety of sitagliptin in older participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)

14. Ausgangscharakteristika der DECLARE-TIMI-58-Studienpopulation

16. Efficacy of sotagliflozin 400 mg/day in 1402 patients with type 1 diabetes treated with any insulin regimen (inTandem 3)

17. Corrigendum to: Incidence and outcomes of emergent cardiac surgery during transfemoral transcatheter aortic valve implantation (TAVI): insights from the European Registry on Emergent Cardiac Surgery during TAVI (EuRECS-TAVI)

18. Ezetimibe added to statin therapy after acute coronary syndromes

19. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

33. Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study.

35. Preventing macrovascular complications in type 2 diabetes mellitus: glucose control and beyond.

41. Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease

42. Comparison of coronary artery calcium detected by electron beam tomography in patients with to those without symptomatic coronary heart disease.

44. Effects of ertugliflozin on uric acid and gout-related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from VERTIS CV.

45. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials.

46. Hypoglycaemia and kidney events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial.

47. Sodium-Glucose Cotransporter 2 Inhibitors and Mycotic Genital or Urinary Tract Infections in Heart Failure.

48. Effects of an Intervention to Improve Evidence-Based Care for People With Diabetes and Cardiovascular Disease Across Sex, Race, and Ethnicity Subgroups: Insights From the COORDINATE-Diabetes Trial.

49. What the SELECT trial of semaglutide means for clinicians.

50. New Perspectives in Management of Cardiovascular Risk Among People With Diabetes.

Catalog

Books, media, physical & digital resources